Joaquina C. Baranda, MD

Professional Background

Dr. Baranda received her medical degree from the University of Santo Thomas in the Philippines in 1985 and completed her residency in internal medicine at Cook County Hospital in Chicago. Prior to joining KU Cancer Center she was an assistant professor at the University of Southern California Norris Comprehensive Cancer Center as a GI oncologist, specialty care physician at Kansas City Veterans Administration Medical Center and medical director of clinical development and medical affairs at a biotech company as the medical lead for multi-center phase I trials.

She is an active member of the Society for Immunotherapy in Cancer, European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO).

• MD, Univ. of Santo Thomas
• Other, University of Southern California, Los Angeles, CA, Los Angeles, CA

• KS Board of Healing Arts, KS Board of Healing Arts

• Hospital Physician Hematology-Oncology Board Review Manual (BRM), Ad Hoc reviewer, 2018 - Present
• University of Kansas Medical Center, Clinical Research Leadership Committee, University of Kansas Medical Center, Clinical Research Leadership Committee, Member, 2017 - Present
• University of Kansas Medical Center, Data Monitoring and Safety Committee, University of Kansas Medical Center, Data Monitoring and Safety Committee, Member, 2017 - Present
• University of Kansas Medical Center, Drug Discovery, Delivery and Experimental Therapeutics Research Program, University of Kansas Medical Center, Drug Discovery, Delivery and Experimental Therapeutics Research Program, Member, 2017 - Present
• University of Kansas Medical Center, Institute for Advancing Medical Innovation, University of Kansas Medical Center, Institute for Advancing Medical Innovation, Member, 2017 - Present
• University of Kansas Medical Center, Investigator Initiated Trail Steering Committee and Executive Committee, University of Kansas Medical Center, Investigator Initiated Trail Steering Committee and Executive Committee, Member, 2017 - Present
• University of Kansas Medical Center, Multidisciplinary Tumor Board, University of Kansas Medical Center, Multidisciplinary Tumor Board, Chair, 2017 - Present

---

Research

Overview

Joaquina Baranda, MD, focuses her research on drug development and early therapeutics through investigator initiated trials, national and industry sponsored trials. She has served as the principal investigator in phase I, II and III clinical trials in gastrointestinal cancers and later as an early phase investigator in different malignancies. Dr. Baranda is one of the leaders in translational clinical trial development at KU Cancer Center and nationally through the Southwest Oncology Group (now known as SWOG) with active roles in the GI working group.

Dr. Baranda leads the Early Phase research unit at KU Cancer Center with the goal of increasing patient access to novel agents and developing translational investigations with biomarker development leading to precision medicine. She is the co-chair of the KU Cancer Center Investigator Initiated Trial Executive Committee. For many years she served as Chair of KU Cancer Center’s Cancer Program Education Committee, the Multidisciplinary Tumor Conference and was leader of GI oncology.

• A PHASE 1 2, OPEN-LABEL, MUL TICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH BEMPEGALDESLEUKIN {NKTR-214) AND IN COMBINATION WITH BEMPEGALDESLEUKIN, Nektar Therapeutics, PI

• Khan, Qamar., J, Bohnenkamp, Colleen, Monson, Taylor, Smith, Holly., E, Phadnis, Milind., A, Raja, Vinay, Elia, Manana, O'Dea, Anne, Crane, Gregory., James, Fesen, Mark., Robert, Nye, Lauren., Elizabeth, Sheehan, Maureen, Pluenneke, Robert., E, Al-Rajabi, Raed., Moh'd Taiseer, Baranda, Joaquina., C, Kasi, Anup, McKittrick, Richard. 2023. Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. Journal of Clinical Oncology, 16 Supl. https://www.webofscience.com/wos/woscc/full-record/WOS:001053772000120
• Williamson, Stephen., K., Hodi, F.., Stephen, Johnson, Melissa., Lynne, Barve, Minal., A., Juric, Dejan, Baranda, Joaquina., Celebre, Schneider, Reva., Elaine, Bauer, Todd., Michael, Lin, Tun., Tun, Wang, Rui, Amrate, Amele, Guillemin-Paveau, Helene, Sullivan, Ryan., J.. 2021. Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.. Journal of Clinical Oncology, 39 (15_suppl), 2510-2510. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2510
• Saeed, A, Park, R, Pathak, H, Al-Bzour, A., N, Dai, J, Phadnis, M, Al-Rajabi, R, Kasi, A, Baranda, J, Sun, W, Williamson, S, Chiu, Y., C, Osmanbeyoglu, H., U, Madan, R, Abushukair, H, Mulvaney, K, Godwin, A., K, Saeed, A. 2024. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.. Nature communications, 15 (1), 1533
• Freed, I., M, Kasi, A, Fateru, O, Hu, M, Gonzalez, P, Weatherington, N, Pathak, H, Hyter, S, Sun, W, Al-Rajabi, R, Baranda, J, Hupert, M., L, Chalise, P, Godwin, A., K, A Witek, M, Soper, S., A. 2023. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients.. Cells, 12 (18)
• Acuña-Villaorduña, A, Baranda, J., C, Boehmer, J, Fashoyin-Aje, L, Gore, S., D. 2023. Equitable Access to Clinical Trials: How Do We Achieve It?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43, e389838
• Richardson, G., E, Al-Rajabi, R, Uprety, D, Hamid, A, Williamson, S., K, Baranda, J, Mamdani, H, Lee, Y., L, Nitika, Li , L, Wang, X, Dong, X. 2023. A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.. Cancers, 15 (9)
• Jimeno, A, Baranda, J, Iams, W., T, Park, J., C, Mita, M, Gordon, M., S, Taylor, M, Dhani, N, Leal, A., D, Neupane, P, Eng, C, Yeku, O, Mita, A, Moser, J., C, Butler, M, Loughhead, S., M, Jennings, J, Miselis, N., R, Ji, R., R, Nair, N, Kornacker, M, Zwirtes, R., F, Bernstein, H, Sharei, A. 2023. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.. Investigational new drugs. https://www.webofscience.com/wos/woscc/full-record/WOS:000943152500001
• Saeed, A, Park, R, Dai, J, Al-Rajabi, R, Kasi, A, Baranda, J, Williamson, S, Saeed, A, Ripp, J, Collins, Z, Mulvaney, K, Shugrue, M, Firth-Braun, J, Godwin, A., K, Madan, R, Phadnis, M, Sun, W. 2023. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.. Cell reports. Medicine, 4 (2), 100916
• Baranda, J., C, Diaz, F., J, Rubinstein, L, Shields, A., F, Dayyani, F, Mehta, A, Mehnert, J., M, Trent, J, Mabaera, R, Mooney, M, Moscow, J., A, Doroshow, J, Waters, B, Ivy, P, Gore, S., D, Thomas, A. 2022. Expanding Access to Early Phase Trials: The CATCH-UP.2020 Experience.. JNCI cancer spectrum. https://europepmc.org/article/MED/36525371#free-full-text